三阴性乳腺癌免疫治疗研究进展

Research progress on immunotherapy for triple-negative breast cancer

三阴性乳腺癌(TNBC)是雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER2)表达阴性的乳腺癌亚型,具有侵袭性强、易复发转移等特点。因为缺乏治疗靶点,化疗是其主要治疗手段。近年来,免疫治疗在三阴性乳腺癌的治疗中取得众多进展。本综述总结了三阴性乳腺癌免疫治疗的主要方式,包括免疫检查点抑制剂、过继性免疫细胞疗法、肿瘤疫苗和溶瘤病毒疗法。我们从临床研究和基础研究角度介绍了各治疗方式的最新研究进展,并介绍了免疫治疗潜在的疗效预测生物标志物与耐药机制。

Triple-negative breast cancer(TNBC)is a subtype of breast cancer characterized by the absence of estrogen receptor(ER),progesterone receptor(PR),and human epidermal growth factor receptor 2(HER2).It is highly aggressive,easy to relapse,and chemotherapy remains its mainstay treatment due to the lack of therapeutic targets.In recent years,many advances have been made in the development of immunotherapy for TNBC.This review summarizes the primary modalities of immunotherapy for TNBC,including immune checkpoint inhibitors,adoptive immune cell therapy,tumor vaccines and oncolytic virus.We present the latest research progress on each treatment from the perspective of clinical study and fundamental research,while introducing the potential predictive biomarkers and resistance mechanisms of immunotherapy for TNBC.